Qure.ai's AI X-ray for Lung Nodules Gets USFDA Clearance
Qure.ai's AI-powered chest X-ray solution for lung nodule detection receives USFDA clearance, marking the company's 6th clearance for chest X-ray solutions.

New Delhi, Jan 10 (PTI) Medical imaging solutions provider Qure.ai on Wednesday said it has received clearance from US health regulator for its artificial intelligence-enabled X-ray for detection of lung nodules.
Qure's chest X-ray-based qXR-LN uses artificial intelligence (AI)to identify and localize lung nodules thereby helping in identifying potentially malignant pulmonary nodules, thus boosting the fight against lung cancer, the company said in a statement.
This also marks the 6th USFDA (United States Food and Drug Administration) clearance for Qure's chest X-ray based solutions, the company said.
The qXR for lung nodule is a cutting-edge detection software designed to identify and highlight regions indicative of suspected pulmonary nodules ranging from 6 to 30 mm in size.
Prashant Warier, Co-Founder and CEO of Qure.ai, said the company has already deployed and implemented this solution globally, and the USFDA clearance "marks yet another ground-breaking leap in our pioneering efforts to combat lung cancer".
"Our heightened emphasis on the North American marketplace solidifies our commitment to making a meaningful impact in the fight against this deadly disease and underscores our dedication to advancing healthcare through innovation, providing a transformative solution enhancing the early detection of cancer and ultimately improving patient outcomes," Warier said.
Qure's chest X-ray-based qXR-LN uses artificial intelligence (AI)to identify and localize lung nodules thereby helping in identifying potentially malignant pulmonary nodules, thus boosting the fight against lung cancer, the company said in a statement.
This also marks the 6th USFDA (United States Food and Drug Administration) clearance for Qure's chest X-ray based solutions, the company said.
The qXR for lung nodule is a cutting-edge detection software designed to identify and highlight regions indicative of suspected pulmonary nodules ranging from 6 to 30 mm in size.
Prashant Warier, Co-Founder and CEO of Qure.ai, said the company has already deployed and implemented this solution globally, and the USFDA clearance "marks yet another ground-breaking leap in our pioneering efforts to combat lung cancer".
"Our heightened emphasis on the North American marketplace solidifies our commitment to making a meaningful impact in the fight against this deadly disease and underscores our dedication to advancing healthcare through innovation, providing a transformative solution enhancing the early detection of cancer and ultimately improving patient outcomes," Warier said.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- NTPC
- 330.60 ( -0.93)
- 97490956
- Vodafone Idea L
- 6.87 (+ 4.89)
- 80402624
- Sharanam Infra
- 0.39 ( -4.88)
- 58299215
- Remedium Lifecare
- 0.84 ( -4.55)
- 31319171
- Sunshine Capital
- 0.35 ( -2.78)
- 23732267